Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Medpace Holdings, Inc. (MEDP)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP). The investigation concerns whether Medpace and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

[Click here to learn more about the investigation]

On July 22, 2024, Medpace released its second quarter 2024 financial results, significantly missing expectations. In an earnings call the next day, the Company stated that “cancellations were disproportionately high in the month of June” due to “reprioritization, impaired sponsor liquidity, and acquisition of one sponsor by a large pharma with subsequent decision to move the work to an existing preferred provider.” On this news, the price of Medpace shares declined by $79.88, or approximately 18.3%, from $437.18 on July 22, 2024 to close at $357.30 per share on July 23, 2024.

If you purchased or otherwise acquired Medpace securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at [e-mail], or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.